SPM 011Alternative Names: SPM-011
Latest Information Update: 27 Apr 2016
At a glance
- Originator Stella Pharma
- Developer Osaka University; Stella Pharma; Sumitomo Heavy Industries
- Class Antineoplastics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Glioma
Most Recent Events
- 27 Apr 2016 Phase-II clinical trials in Glioma (Recurrent) in Japan (IV)